Overview: 17-Hydroxy-Progesterone TestIntroduction: The 17-Hydroxy-Progesterone Test measures 17-hydroxyprogesterone, a hormone produced by the adrenal glands, to diagnose disorders like congenital adrenal hyperplasia (CAH), which can lead to abnormal growth, early puberty, or fertility issues. Following 2023 Endocrine Society guidelines, it uses an immunoassay for high accuracy, aiding in the confirmation of adrenal disorders. This test is essential for guiding hormone therapy, preventing complications like infertility, and improving outcomes in endocrinology.
Other Names: 17-OHP Assay, 17-Hydroxyprogesterone Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: Linked to CAH in the 1960s, 17-hydroxyprogesterone testing improved with immunoassays in the 1980s. By the 2000s, automated assays enhanced reliability for adrenal screening.
Purpose: Diagnoses CAH or other adrenal disorders, guides hormone therapy, and monitors disease in patients with symptoms like early puberty or infertility.
Test Parameters: 1. 17-Hydroxyprogesterone
Pretest Condition: Fasting for 10-12 hours is required. Collect serum, plasma, or saliva in the morning due to diurnal hormone variation. Report symptoms like early puberty, infertility, or steroid use.
Specimen: 2-5 mL serum (SST), 2-4 mL plasma (EDTA), or 1-2 mL saliva (sterile container). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours, light-protected.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document symptoms such as abnormal growth, early puberty, infertility, or a family history of CAH or endocrine disorders. Include current medications or hormonal treatments.
Consent: Written consent is required, outlining the test's purpose, diagnostic implications, and potential need for hormone therapy.
Procedural Considerations: Employs an immunoassay (ELISA or radioimmunoassay) to measure 17-hydroxyprogesterone. Results are available in 1-2 days, facilitating timely diagnosis.
Factors Affecting Result Accuracy: Steroids or biotin supplements may cause false results. Hemolysis or improper storage can affect sample quality. Morning collection is critical for accuracy.
Clinical Significance: Elevated 17-hydroxyprogesterone levels confirm CAH, prompting hormone therapy. Normal levels may require ACTH stimulation or genetic testing for confirmation.
Specialist Consultation: Consult an endocrinologist for result interpretation. Genetic counseling is advised for CAH or familial endocrine disorders.
Additional Supporting Tests: ACTH, cortisol, or CYP21A2 gene testing to confirm CAH or assess adrenal function.
Test Limitations: False results may occur with medications or improper sample timing. Mild CAH may require stimulation testing for detection.
References: Endocrine Society CAH Guidelines, 2023; White PC, Endocrine Reviews, 2022.
